Role of ubiquitination in PCSK9-mediated low-density lipoprotein receptor degradation

Biochemical and Biophysical Research Communications

Volumn 415, Issue 3, 2011, Pages 515-518

  Chen, Yanqun ^a   Wang, He ^a   Yu, Lan ^a   Yu, Xiaohong ^a   Qian, Yue wei ^a   Cao, Guoqing ^a   Wang, Jian ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Low density lipoprotein receptor; PCSK9; Protein degradation; Ubiquitin

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; LOW DENSITY LIPOPROTEIN RECEPTOR; LYSINE; PROPROTEIN CONVERTASES SUBTILISIN KEXIN 9; PROTEASOME; SERINE PROTEINASE; UNCLASSIFIED DRUG;

ARTICLE; CARBOXY TERMINAL SEQUENCE; DRUG EFFECT; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; UBIQUITINATION;

HEK293 CELLS; HUMANS; PROTEASOME ENDOPEPTIDASE COMPLEX; RECEPTORS, LDL; SERINE ENDOPEPTIDASES; UBIQUITINATION;

EID: 82355191522     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.10.110     Document Type: Article

References (17)

1. Zhang D.W., Lagace D.A., Garuti R., et al. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat a of low density lipoprotein receptor decreases receptor recycling and increases degradation. J. Biol. Chem. 2007, 282:18602-18612.
2. Qian Y.W., Schmidt R.J., Zhang Y., et al. Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis. J. Lipid Res. 2007, 48:1488-1498.
3. Maxwell K.N., Fisher E.A., Breslow J.L. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc. Natl. Acad. Sci. USA 2005, 102:2069-2074.
4. Scartezini M., Hubbart C., Whittall R.A., et al. The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in healthy U.K. men. Clin. Sci. 2007, 113:435-441.
5. Abifadel M., Varret M., Rabes J.P., et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 2003, 34:154-156.
6. Cohen J.C., Boerwinkle E., Mosley T.H., Hobbs H.H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 2006, 354:1264-1272.
7. Horton J.D., Cohen J.C., Hobbs H.H. PCSK9: a convertase that coordinates LDL catabolism. J. Lipid Res. 2009, 50:S172-S177.
8. Cohen P., Tcherpakov M. Will the ubiquitin system furnish as many drug targets as protein kinases?. Cell 2010, 143:686-693.
9. Deshaies R.J., Joazeiro C.A.P. RING domain E3 ubiquitin ligases. Annu. Rev. Biochem. 2009, 78:399-434.
10. Sitia R., Braakman I. Quality control in the endoplasmic reticulum protein factory. Nature 2003, 426:891-894.
11. Miranda M., Sorkin A. Regulation of receptors and transporters by ubiquitination: new insights into surprisingly similar mechanisms. Mol. Interv. 2007, 7:157-167.
12. Mukhopadhyay D., Riezman H. Proteasome-independent functions of ubiquitin in endocytosis and signaling. Science 2007, 315:201-205.
13. Poirier S., Mayer G., Poupon V., et al. Dissection of the endogenous cellular pathways of pcsk9-induced low density lipoprotein receptor degradation. J. Biol. Chem. 2009, 284:28856-28864.
14. Zelcer N., Hong C., Boyadjian R., Tontonoz P. LXR regulates cholesterol uptake through idol-dependent ubiquitination of the LDL receptor. Science 2009, 325:100-104.
15. Hong C., Duit S., Jalonen P., et al. The E3 ubiquitin ligase IDOL induces the degradation of the low density lipoprotein receptor family members VLDLR and ApoER2. J. Biol. Chem. 2010, 285:19720-19726.
16. Martin N.P., Lefkowitz R.J., Shenoy S.K. Regulation of V2 vasopressin receptor degradation by agonist-promoted ubiquitination. J. Biol. Chem. 2003, 278:45954-45959.
17. Scotti E., Hong C., Yoshinaga Y., et al. Targeted disruption of the idol gene alters cellular regulation of the low-density lipoprotein receptor by sterols and liver x receptor agonists. Mol. Cell Biol. 2011, 31:1885-1893.